IDSA 2011: Components of Effective HIV Care [Video]

Article

In this video, Joel Gallant, MD, lead author, board member at HIVMA, associate director at Johns Hopkins AIDS Service, discusses issues related to a policy paper recently released by the HIV Medicine Association.

An IDSA Public Policy was released today titled, "Essential Components of Effective HIV Care: A briefing on a policy paper by the HIV Medicine Association and the Ryan White Medical Providers Coalition," authored by the HIV Medical Association and Ryan White Medical Providers Coalition, which describes the ideal HIV comprehensive care model and calls for innovative payment mechanisms and continued public health funding to support this care and expand it to those who need it.

Joel Gallant, MD, lead author, board member at HIVMA, associate director at Johns Hopkins AIDS Service, Mari Kitahata, MD, MPH, professor of medicine at the University of Washington, and Kevin Carmichael, MD, co-chair of the Ryan White Medical Providers Coalition, chief of service at El Rio Special Immunology Associates in Tucson, briefly discussed the policy paper and answered various questions about the impact of the Patient Protection and Affordable Care Act will have on the care provided to HIV patients, the need to have HIV measures considered for the next phase of the Medicare and Medicaid EHR Incentive Program, and whether the policy paper will be circulated to members of Congress with the hopes of having legislation developed on the problems Gallant, Kitahata, and Carmichael spoke about.

When asked about if having legislation developed by the federal government, Gallant responded saying, "There are a lot of unknowns in regards to health care reform and the next election."

Related Videos
HCPLive Five at ACC 2024 | Image Credit: HCPLive
Ankeet Bhatt, MD, MBA | Credit: X.com
Ankeet Bhatt, MD, MBA | Credit: X.com
Sara Saberi, MD | Credit: University of Michigan
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Veraprapas Kittipibul, MD | Credit: X.com
Addressing HS Risks at the Genetic Level, with Kai Li, BSc
Building a Psoriasis Knockout Regimen Around Risankizumab, with Andrew Blauvelt, MD, MBA
© 2024 MJH Life Sciences

All rights reserved.